Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KLK7 | P49862 | 2/20 | 0.47 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15249567 | 0.96 | MAPT (0.45) | MAPTKLK7KLK5ITGB3ITGA2B | |
| SCHEMBL16762136 | 0.92 | ALB (0.43) | ALBFOLH1 | |
| SCHEMBL21543552 | 0.90 | MAPT (0.57) | MAPTKLK7KLK5ITGB3ITGA2B | |
| SCHEMBL21712193 | 0.89 | MAPT (0.51) | MAPTKLK7KLK5ITGB3ITGA2B | |
| SCHEMBL8829501 | 0.89 | MAPT (0.51) | MAPTKLK7KLK5ITGB3ITGA2B | |
| SCHEMBL29627386 | 0.89 | MAPT (0.51) | MAPTKLK7KLK5ITGB3ITGA2B | |
| SCHEMBL21715278 | 0.88 | MAPT (0.54) | MAPTKLK7KLK5ITGB3ITGA2B | |
| SCHEMBL29627379 | 0.88 | MAPT (0.54) | MAPTKLK7KLK5ITGB3ITGA2B | |
| SCHEMBL23357782 | 0.88 | MAPT (0.54) | MAPTKLK7KLK5ITGB3ITGA2B | |
| SCHEMBL15238819 | 0.87 | CTSK (0.45) | CTSKALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11484524-B2 | Compositions and methods to improve adoptive cell therapies | 7 Hills Pharma LLC (US) | 2022-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11484524-B2 | Compositions and methods to improve adoptive cell therapies | ITGB7, ITGB1, ITGA1 | MAPT 4198/4885KLK7 260/4885KLK5 1198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.